Finland· FI-REL-REL48935
Adynovi
A coagulation factor viii product containing rurioctocog alfa pegol, registered in Finland by Baxalta Innovations GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against Fimea (Finland) on
Informational only — not a medical device.
Where it is registered
Coagulation factor viii is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BD02 (coagulation factor viii), each read from that country’s own register.
- This record: Finland, from Fimea (Finland)
- 7 of them publish a price we can compare per daily dose
Coagulation factor viii · ATC B02BD02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Fimea (Finland)- Active substance
- Rurioctocog alfa pegol
- Manufacturer
- Baxalta Innovations GmbH
- Country
- Finland (FI)
- ATC code
- B02BD02
- ATC class
- Coagulation factor VIII
- Defined daily dose
- 1 TSD, E
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
4 interactions on record for coagulation factor viii.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Coagulation factor viii · interactions on record
4 records
- 2 severe
- 2 moderate
Most severe, free to view
- CarfilzomibL01XG02severe
- CarfilzomibL01XX45severe
- PegvaliaseA16AB19moderate
- EmicizumabB02BX06moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Coagulation factor viii in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- IrelandADYNOVI 500 IU Powder and solvent for solution for injectionBaxalta Innovations GmbH
- SwitzerlandAdynovi
- CzechiaADYNOVIBaxalta Innovations GmbH, Vídeň
- BelgiumAdynovi 1000 IU/2 mlBaxalta Innovations
- SwedenADYNOVI 1000 IE/2 ml Pulver och vätska till injektionsvätska, lösningBaxalta Innovations GmbH
- IcelandAdynoviBaxalta Innovations GmbH
- NetherlandsAdynovi 1000 IE/2 ml, poeder en oplosmiddel voor oplossing voor injectieBaxalta Innovations GmbH
- Japanルリオクトコグ アルファ ペゴル(遺伝子組換え)武田薬品工業
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Adynovi
- Liechtenstein · Adynovi
- Norway · Adynovi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/05b82a09-1a43-4bd4-beae-8202930d1ecd GET /v1/drugs/05b82a09-1a43-4bd4-beae-8202930d1ecd?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "injektiokuiva-aine ja liuotin, liuosta varten",
"route": "Laskimoon",
"ddd_unit": null,
"strength": "500 IU",
"atc_label": "hyytymistekijä VIII",
"ma_number": null,
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": "EU/1/17/1247/005-008",
"fimea_rel_id": "REL48935",
"authorised_at": "2018-01-08"
}See everything about coagulation factor viii.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.